|
FBXO9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.62099999995369E-06 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
7.820200E-02 |
| Stage1-vs-Stage3 |
4.081000E-03 |
| Stage1-vs-Stage4 |
8.621200E-04 |
| Stage2-vs-Stage3 |
1.422550E-03 |
| Stage2-vs-Stage4 |
2.003100E-04 |
| Stage3-vs-Stage4 |
2.753200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.20539999981517E-07 |
| Normal-vs-Asian |
1.08559827793897E-11 |
| Caucasian-vs-AfricanAmerican |
5.010200E-01 |
| Caucasian-vs-Asian |
2.027000E-01 |
| AfricanAmerican-vs-Asian |
8.519400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
5.060000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
4.66293670342566E-15 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
3.222700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.071800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.481750E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.147200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.097950E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.131200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.697000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.40649714097663E-11 |
| Classical-VS-Follicular |
4.058900E-03 |
| Classical-VS-Other |
3.283200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.97539770599542E-13 |
| Tall-VS-Other |
1.772960E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
8.783700E-02 |
| Follicular-VS-Normal |
7.21249999724449E-08 |
| Other-VS-Normal |
3.35380000004992E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.25566224085105E-13 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
6.05759999999789E-05 |
|
|
